High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Cell Host & Microbe
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission

Graphical Abstract

Highlights

- Developed SaLSSA, a serum-free one-step assay for malaria transmission-blocking activity
- 13,983 known and new compounds analyzed by SaLSSA
- >90% known antimalarial drugs do not show activity against late-stage gametocytes
- Compounds with consistent low nanomolar transmission-blocking activity identified

Authors
David M. Plouffe, Melanie Wree, Alan Y. Du, ..., Christina A. Scherer, Joseph Vinetz, Elizabeth A. Winzeler

Correspondence
ewinzeler@ucsd.edu

In Brief
Preventing human-mosquito transmission is important for malaria control. Plouffe et al. developed SaLSSA, a one-step high-throughput assay to screen for malaria transmission-blocking activity. A large panel of known and new small molecules was analyzed by SaLSSA. This provides starting points for the discovery and development of transmission-blocking drugs.

Plouffe et al., 2016, Cell Host & Microbe 19, 114–126
January 13, 2016 ©2016 The Authors
http://dx.doi.org/10.1016/j.chom.2015.12.001
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission

David M. Plouffe,1,7 Melanie Wree,2,7 Alan Y. Du,2 Stephan Meister,2 Fengwu Li,3 Kailash Patra,3 Aristea Lubar,3 Shinni L. Okitsu,2,8 Erika L. Flannery,2 Nobutaka Kato,4 Olga Tanaseichuk,1 Eamon Comer,1 Bin Zhou,1 Kelli Kuhen,1 Yingyao Zhou,1 Didier Leroy,5 Stuart L. Schreiber,4,6 Christina A. Scherer,4 Joseph Vinetz,3 and Elizabeth A. Winzeler2,*

1The Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA
2Division of Infectious Disease, Department of Medicine
University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
3Division of Pharmaceutical and Drug Discovery, Department of Pediatrics
University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
4Broad Institute, 415 Main Street, Cambridge MA 02142
5Medicines for Malaria Venture (MMV), PO Box 1826, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland
6Department of Chemistry and Chemical Biology, Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA
7Co-first author
8Present address: EMD Serono Research and Development Institute, Billerica, MA 02370, USA
*Correspondence: ewinzeler@ucsd.edu
http://dx.doi.org/10.1016/j.chom.2015.12.001
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0).

SUMMARY

Preventing transmission is an important element of malaria control. However, most of the current available methods to assay for malaria transmission blocking are relatively low throughput and cannot be applied to large chemical libraries. We have developed a high-throughput and cost-effective assay, the Saponin-lysis Sexual Stage Assay (SaLSSA), for identifying small molecules with transmission-blocking capacity. SaLSSA analysis of 13,983 unique compounds uncovered that >90% of well-characterized antimalarials, including endoperoxides and 4-aminoquinolines, as well as compounds active against asexual blood stages, lost most of their killing activity when parasites developed into metabolically quiescent stage V gametocytes. On the other hand, we identified compounds with consistent low nanomolar transmission-blocking activity, some of which showed cross-reactivity against asexual blood and liver stages. The data clearly emphasize substantial physiological differences between sexual and asexual parasites and provide a tool and starting points for the discovery and development of transmission-blocking drugs.

INTRODUCTION

Malaria is a vector-borne disease caused by apicomplexan eukaryotic protozoa of the genus Plasmodium. The parasites have a complex life cycle involving vertebrates and anopheline mosquitoes. Their asexual replication and destruction of erythrocytes give rise to the symptoms of malaria, including fever and chills. In response to cues that are not well understood, a subset of asexual parasites differentiate into male and female gametocytes (Sinden, 1983), a process that takes ~8–12 days in P. falciparum (Sinden, 2009). During this period, the parasites metabolize the host red cell hemoglobin (Hanssen et al., 2012), while progressing through five morphologically distinct stages that can be identified by light microscopy (Carter and Miller, 1979). Commitment to sexual development occurs well before parasites show morphological changes, and male and female gametocytes are produced at a ratio of 1 to 3–5 (Gbotosho et al., 2011; Robert et al., 2003) with females maturing slightly later (Bounkeua et al., 2010). In the human body, immature gametocytes sequester in different host tissues (Rogers et al., 2000) and emerge only when fully mature. An infected individual may carry gametocytes for up to 55 days (Bousema et al., 2010), and mature gametocytes are the only form that can survive in the mosquito midgut, mate, undergo meiosis, and give rise to the next generation of parasites to be transmitted to a new human host.

Current first-line treatment of falciparum malaria is artemisinin combination therapies (ACTs) (WHO, 2015), which do not block transmission. Follow-up treatment with 8-aminoquinolines like primaquine or tafenoquine is needed to block transmission (Eziefula et al., 2014). However, 8-aminoquinolines can be toxic to individuals with glucose-6-phosphate dehydrogenase deficiency, a genetic condition with a high prevalence in malaria-endemic regions (Luzzatto, 1979).

Even though assays are available to detect compounds with transmission-blocking potential (Adjalley et al., 2011; Almela et al., 2015; D’Alessandro et al., 2013; Delves et al., 2012b; Duffy and Avery, 2012; Lelièvre et al., 2012; Lucantoni et al., 2013; Miguel-Blanco et al., 2015; Ruecker et al., 2014; Sun et al., 2014; Tanaka et al., 2013), most of them are not adapted for very large chemical libraries due to multiple purification steps or lower throughput formats. In addition, some assays rely on the use of gametocyte reporters that may restrict their use to genetically modified parasites (Adjalley et al., 2011; Peatey et al., 2011). Here we describe high-throughput assays that overcome these...
We apply the assays to characterized and uncharacterized chemical libraries. Our analysis reveals features of chemical compounds that are likely to block malaria transmission and may serve as starting points for unique transmission-blocking drugs.

RESULTS

Developing an Assay to Identify Compounds with Transmission-Blocking Activity

Production of Homogeneous Populations of Gametocytes

To create a homogeneous, stage-specific gametocyte population, we optimized a previously described protocol (Fivelman et al., 2007) and induced gametocytogenesis in asexual, triple synchronized P. falciparum NF54 parasites by high parasitemia and partly spent media (Figure 1A: Experimental Procedures). Microscopic staging of gametocytes collected over the 12 days of development according to description by Carter and Miller (1979) showed purities upward of 75% per stage (Figure 1C) with a reproducible parasitemia of 1.2%–1.6% over the screening period (data not shown).

Measuring Viability in Non-Replicating Parasites

To detect viability, we used the dye MitoTracker Red CMXRos (MTR Red), which fluoresces at 560 nm in parasites with intact mitochondrial membrane potential (Pendergrass et al., 2004; Poot et al., 1996) (Figure 1B). Parasites were detected using high content imaging and analysis.

Figure 1. Induction and Development of Pure, Stage-Specific Gametocytes

(A) Gametocyte production protocol. To create stages I–IV, all steps were performed, but to create stage V only, steps indicated by red boxes were omitted. (B) Simplified schematic flow chart for the SaLSSA gametocyte assay. (C) Giemsa smears of gametocytes of stage I–V and gametocyte counts and percentages for each stage based on their morphology (numbers pooled from multiple cycles). (D) Z prime values for the different gametocyte stages and assay protocols. 1384-well TSSA, stages I–V, 2384-well SaLSSA, stages I–V, 31,536-well SaLSSA, stage V. (E) Displayed is the number of viable stage V gametocytes in a dilution series over time (0.5 hr until 6 hr). These data were acquired using stage V gametocytes and 1,536-well SaLSSA (R² > 0.99).
automated microscopy and showed a good correlation ($R^2 = 0.99$) between the number of viable parasites added per well and the number of MitoTracker Red CMXRos positive objects (Figure 1E).

**Reduction in Number of Liquid-Transfer Steps**

To reduce the number of liquid transfer steps and make the assay more robust and less costly for use with large, unbiased libraries, we experimented with the use of saponin, an amphi-pathic glycoside that creates pores in red cell membrane bilayers, leading to red cell lysis (Baumann et al., 2000). We found that treating gametocyte cultures with 0.13% saponin caused red blood cells in serum-free media to lyse, simplifying the identification of parasites with automated microscopy. Gametocytes at a parasitemia of 0.5% to 0.75% and a hematocrit of 1.25% created a monolayer on the bottom of the well. After MTR Red staining ~1,000 objects could be counted per DMSO control well (1,536) (Figure 1E). This allowed compound exposure and imaging in the same plate without an additional transfer step. We refer to this serum-free one-step protocol as Saponin-Lysis Sexual Stage Assay (SaLSSA). We found SaLSSA to be more sensitive to few compounds like the amino alcohols (see below). Thus, an older, serum-containing assay (two-step sexual stage assay or TSSA) was used in some cases.

**Assay Evaluation**

The quality of the assay was found to be robust at all gametocyte stages: Z prime scores calculated with infected, DMSO-treated red blood cells and uninfected red blood cells ranged from 0.71 to 0.80 for the one-step protocols (Figure 1D). We evaluated the fluorescence intensity over time and did not observe significant differences between 30 and 360 min (data not shown).

**Evaluation of Known Antimalarial Drugs Shows Only Few Compounds with Activity against Late-Stage Gametocytes**

To further benchmark SaLSSA, we evaluated 50 compounds currently used as antimalarials or antimalarial tool compounds (Delves et al., 2012a) in dose response against individual gametocyte stages. EC$_{50}$ values of different chemical classes showed distinct patterns of activity for the different gametocyte stages as summarized below (Tables 1 and S1). Most compounds yielded higher EC$_{50}$ against stage V gametocytes.

**Endoperoxides**

Endoperoxides were characterized by low nM EC$_{50}$ values for stages I–IV with most failing to generate a dose-response curve for stage Vs, in agreement with standard membrane-feeding data: Although DHA, artesunate, and OZ439 have been reported to have some activity in standard membrane-feeding assays (SMFAs) (Bolscher et al., 2015; Delves et al., 2012a), none completely eliminated oocysts at 100 nM, and only OZ439 eliminated oocysts at 1 μM, a concentration well above the concentrations in blood when being used against blood-stage infections (Bolscher et al., 2015). Interestingly, these results correlate well with previous publications reporting that hemoglobin digestion ends at stages III to IV (Hayward, 2000; Lang-Unnasch and Murphy, 1998), supporting the endoperoxides’ activity against this process (Klonis et al., 2011).

**8-Aminoquinolines**

The 8-aminoquinolines showed consistent but high (μM) EC$_{50}$ values across all gametocyte stages. Primaquine, the only drug approved for blocking transmission, exhibited a 6.5 μM EC$_{50}$ against stage V gametocytes in vitro. Tafenoquine, a primaquine derivative, had an EC$_{50}$ of 2.4 μM against stage V gametocytes. The substantially higher EC$_{50}$ than the ED$_{50}$ values were expected because 8-aminoquinolines need to be metabolized for activity. The mechanism of action of primaquine as well as the identity of the active metabolites remains unknown.

**Amino Alcohols**

Amino alcohols are not used to prevent transmission, but some amino alcohols (lumefantrine, mefloquine, and halofantrine, but not quinidine and quinine) showed activity across all stages using SaLSSA. We note, however, that this sensitivity could be completely reversed by the addition of human serum to cultures during compound incubation using the TSSA. Mefloquine only shows SMFA activity at high concentrations (10 μM), ~20x above the asexual growth inhibition values (50 nM). Testing some compounds in the presence of human serum would be expected to give more accuracy and eliminate false positives, but at the expense of efficiency.

**Other Clinically Relevant Compounds**

The antifolates and sulfonamides, which interfere with nucleic acid synthesis and include dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) inhibitors (pyrimethamine, P218, and chlorproguanil), were inactive across all gametocyte stages, except for chlorproguanil, which had μM EC$_{50}$ values against all stages. Antibiotics used to treat malaria, such as doxycycline and azithromycin, which act against the apicoplast, were also inactive. As expected (Fleck et al., 1996), atovaquone was inactive (Table 1). Evidence that this compound has some transmission-blocking activity in animals after repeated exposure (Blagborough et al., 2013) may be because it inhibits ookinete formation (Delves et al., 2012a).

**Antimalarial Compounds with Stage V Activity**

Some antimalarial compounds that are not used in humans did show activity against stage V gametocytes in our assay (Table 1). Thiostrepton is a macrocyclic thiopeteptide antibiotic that inhibits prokaryotic translation (Harms et al., 2008) and has been reported to dually target the proteasome and apicoplast (Aminake et al., 2011). Thiostrepton had μM EC$_{50}$ values at all stages. The mode of action of methylene blue remains controversial, but it may inhibit glutathione reductase (Buchholz et al., 2008) or hemoglobin formation (Adjalley et al., 2011). It showed low nM EC$_{50}$ values for stages I to IV, with some minor loss of activity at stage V, consistent with reports that methylene blue reduced transmission by 99% in SMFAs at 38 nM. Pentamidine, which is clinically used for treatment and prophylaxis of Pneumocystis carinii pneumonia (PCP) and sleeping sickness but not malaria, inhibited gametocytes of all stages with an EC$_{50}$ between 0.39 and 2.14 μM. Its mechanism
<table>
<thead>
<tr>
<th>Compound</th>
<th>Chemical Class</th>
<th>EC₅₀ (µM) ± STD</th>
<th>Oocyst Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artemisin</td>
<td>Endoperoxide</td>
<td>0.024 ± 0.001</td>
<td>75%–99%</td>
</tr>
<tr>
<td>Artemisone</td>
<td>Endoperoxide</td>
<td>0.003 ± 0.000</td>
<td>10 µM: 75%–99%</td>
</tr>
<tr>
<td>Artemether</td>
<td>Endoperoxide</td>
<td>0.016 ± 0.006</td>
<td>10 µM: ~90%</td>
</tr>
<tr>
<td>Artemether (Dihydroartemisin)</td>
<td>Endoperoxide</td>
<td>0.006 ± 0.001</td>
<td>10 µM: ~55%</td>
</tr>
<tr>
<td>Artesunate</td>
<td>Endoperoxide</td>
<td>0.008 ± 0.002</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>OZ439 mesylate</td>
<td>Endoperoxide</td>
<td>0.011 ± 0.001</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>OZ277(RBX-11160)</td>
<td>Endoperoxide</td>
<td>0.008 ± 0.001</td>
<td>10 µM: 75%–99%</td>
</tr>
<tr>
<td>Amodiaquine</td>
<td>4-aminoquinoline</td>
<td>0.012 ± 0.001</td>
<td>10 µM: 50%–74%</td>
</tr>
<tr>
<td>AQ-13</td>
<td>4-aminoquinoline</td>
<td>0.043 ± 0.002</td>
<td>10 µM: 25%–49%</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>4-aminoquinoline</td>
<td>0.096 ± 0.007</td>
<td>10 µM: 25%–49%</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>4-aminoquinoline</td>
<td>0.107 ± 0.011</td>
<td>10 µM: 25%–49%</td>
</tr>
<tr>
<td>Piperaquine phosphate</td>
<td>4-aminoquinoline</td>
<td>0.018 ± 0.002</td>
<td>1 µM: ~25%</td>
</tr>
<tr>
<td>Pyronaridine phosphate</td>
<td>4-aminoquinoline</td>
<td>0.013 ± 0.001</td>
<td>1 µM: ~80%</td>
</tr>
<tr>
<td>Primaquine</td>
<td>8-aminoquinoline</td>
<td>2.467 ± 0.168</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>NPC-1161B</td>
<td>8-aminoquinoline</td>
<td>2.002 ± 0.188</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>Pamaquine (diethylprimaquine)</td>
<td>8-aminoquinoline</td>
<td>1.682 ± 0.318</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>Tafenoquine</td>
<td>8-aminoquinoline</td>
<td>4.560 ± 0.942</td>
<td>38 nM: 99%</td>
</tr>
<tr>
<td>Mefloquine (+ RS)</td>
<td>Amino alcohol</td>
<td>0.038 ± 0.001</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>Halofantrine</td>
<td>Amino alcohol</td>
<td>0.002 ± 0.001</td>
<td>10 µM: 75%–99%</td>
</tr>
<tr>
<td>Lumarfantrine</td>
<td>Amino alcohol</td>
<td>0.013 ± 0.001</td>
<td>1 µM: ~60%</td>
</tr>
<tr>
<td>Mefloquine (Racemic)</td>
<td>Amino alcohol</td>
<td>0.044 ± 0.001</td>
<td>1 µM: ~60%</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Amino alcohol</td>
<td>0.138 ± 0.034</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>Quinine sulfate dihydrate</td>
<td>Amino alcohol</td>
<td>0.440 ± 0.039</td>
<td>10 µM: 100%</td>
</tr>
<tr>
<td>Methylene Blue trihydrate</td>
<td>Aromatic</td>
<td>0.020 ± 0.008</td>
<td>38 nM: 99%</td>
</tr>
<tr>
<td>Thiostrepton</td>
<td>Antibiotic</td>
<td>3.405 ± 0.157</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Doxycyclin</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Cis-Mirincamycin (HCl)</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Trans-Mirincamycin (HCl)</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Fosmidomycin mono sodium</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Antibiotic</td>
<td>&gt;12.500 ± 0.000</td>
<td>10 µM: 0%</td>
</tr>
<tr>
<td>Chlorproguanil hydrochloride</td>
<td>Antifolate</td>
<td>9.350 ± 1.506</td>
<td>4.798 ± 0.758</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>Compound</th>
<th>Chemical Class</th>
<th>EC&lt;sub&gt;50&lt;/sub&gt; (µM) ± STD</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
<th>Stage V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>Antifolate</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Pyrimethamine</td>
<td>Antifolate</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Cycloguanil</td>
<td>Antifolate</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Proguanil hydrochloride</td>
<td>Antifolate</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>P218.HCl</td>
<td>Antifolate</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Sulfadiazine</td>
<td>Sulfonamide</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>Sulfonamide</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Sulfadoxine</td>
<td>Sulfonamide</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Cycloheximide</td>
<td>Other</td>
<td>1.917 ± 0.060</td>
<td>0.640 ± 0.028</td>
<td>0.913 ± 0.027</td>
<td>0.477 ± 0.402</td>
<td>2.692 ± 0.080</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>Other</td>
<td>0.397 ± 0.040</td>
<td>0.591 ± 0.027</td>
<td>0.697 ± 0.016</td>
<td>0.813 ± 0.177</td>
<td>2.143 ± 0.189</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Dehydroepiandrosterone sulfate</td>
<td>Other</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Flavin mononucleotid (Riboflavin)</td>
<td>Other</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>N-acetyl-D-penicillamine</td>
<td>Other</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Deferoxamine mesylate salt</td>
<td>Other</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Puromycin</td>
<td>Control</td>
<td>0.123 ± 0.069</td>
<td>0.122 ± 0.045</td>
<td>0.103 ± 0.039</td>
<td>0.110 ± 0.038</td>
<td>0.122 ± 0.048</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>Atovaquone</td>
<td>Naphthalene</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>GNF179</td>
<td>Imidazolopiperazine</td>
<td>0.341 ± 0.090</td>
<td>0.064 ± 0.017</td>
<td>0.020 ± 0.000</td>
<td>0.009 ± 0.005</td>
<td>0.003 ± 0.001</td>
<td>15 nM: 100%&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>KAI407</td>
<td>Imidazopyrazine</td>
<td>0.593 ± 0.079</td>
<td>0.636 ± 0.057</td>
<td>0.415 ± 0.073</td>
<td>0.329 ± 0.043</td>
<td>0.156 ± 0.026</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>KDU691</td>
<td>Imidazopyrazine</td>
<td>0.532 ± 0.024</td>
<td>0.565 ± 0.009</td>
<td>0.354 ± 0.071</td>
<td>0.237 ± 0.057</td>
<td>0.150 ± 0.001</td>
<td>1 µM: 100%&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>KAF246</td>
<td>Spiroindolone</td>
<td>0.001 ± 0.000</td>
<td>0.002 ± 0.000</td>
<td>0.002 ± 0.000</td>
<td>0.002 ± 0.000</td>
<td>0.002 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
<tr>
<td>DDD107498</td>
<td>Quinoline-4-carboxamide</td>
<td>0.003 ± 0.000</td>
<td>0.005 ± 0.002</td>
<td>0.005 ± 0.001</td>
<td>0.002 ± 0.000</td>
<td>0.009 ± 0.002</td>
<td>EC&lt;sub&gt;50&lt;/sub&gt;&lt;sup&gt;6&lt;/sup&gt; 1.8 nm</td>
</tr>
<tr>
<td>DMSO</td>
<td>Control</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
<td>&gt;12.500 ± 0.000</td>
</tr>
</tbody>
</table>

EC<sub>50</sub> is displayed in µM ± SD (SaLSSA, 384 well in duplicate).

* Amino alcohols (lumefantrine) showed little transmission-blocking activity in the presence of human serum (see Table S1).

<sup>1</sup>Oocyst reductions derived from Bolscher et al. (2015).
<sup>2</sup>Oocyst reductions derived from Adjalley et al. (2011).
<sup>3</sup>Oocyst reductions derived from Delves et al. (2012a).
<sup>4</sup>Oocyst reductions derived from McNamara et al. (2013).
<sup>5</sup>Oocyst reductions derived from this manuscript.
<sup>6</sup>Oocyst reductions derived from Baragaña et al. (2015).
of action is unknown, although it has been reported to inhibit hemozoin formation in *Plasmodium* by interaction with ferriprotoporphyrin IX (Bray et al., 2003; Stead et al., 2001).

**Compounds in Clinical Development**

Newer classes of compounds in development, including the spiroindolones (Rottmann et al., 2010), imidazolopiperazines (Meister et al., 2011), imidazopyrazines (McNamara et al., 2013), and quinoline-4-carboxamides (Baragan˜a et al., 2015), all have reported transmission-blocking activity, and members of these compound classes were tested using SaLSSA (Table 1).

KAF246, a spiroindolone closely related to the clinical candidate KAE609 (also known as cipargamin or NITD609) that acts against the plasma membrane ATPase PfATP4 (Rottmann et al., 2010), showed the expected activity (EC₅₀ = 1 to 2 nM). GNF179, an imidazopiperazine closely related to the clinical candidate KAF156 (Kuhen et al., 2014), showed the expected low nanomolar activity in the SaLSSA and complete transmission-blocking activity in SMFAs at physiologically relevant concentrations of 15 nM (Figures 2 A–2C). The PI(4)K-inhibitor KDU691, which inhibits transmission at 1 μM in SMFAs (McNamara et al., 2013), had submicromolar EC₅₀ values across all five gametocyte stages, similar to the values seen against blood stages (~200 nM). The *Plasmodium falciparum* translation elongation factor 2 (eEF2)-inhibitor, DDD107498, likewise showed potent activity, in line with reported activity in other cellular and standard membrane feeding assays (Baragaña et al., 2015).

**Library 1: MMV Malaria Box Contains Transmission-Blocking Compounds**

To determine whether the loss of activity against stage V parasites was typical or reflects the historical focus on compounds against early-stage gametocytes: 216 compounds inhibited the viability of stage I gametocytes by more than 70%, 78 compounds inhibited stage III gametocytes, and 79 compounds inhibited stage V gametocytes (Table S2).

Dose-response analysis against stage I, III, and V gametocytes for the 50 most active compounds confirmed activity <5 μM for 28 of the 50 compounds with the TSSA. EC₅₀ values for stage V were significantly higher than for stage I gametocytes for 42 of the 50 compounds (Figure 2 D). A few compounds showed EC₅₀ values of ≤1.5 μM against stage V gametocytes in both TSSA and SaLSSA (Table S2), including MMV665941 (stage V EC₅₀ 1.04 μM, SaLSSA, Figure 2B) followed by MMV019918 (stage V EC₅₀ 1.46 μM, SaLSSA). SMFA studies with MMV665941 using GNF179 as a control at a concentration of five and ten times the EC₅₀ calculated from the above described stage V gametocyte assay showed that mosquitoes fed on the compound-exposed gametocytes had no oocysts in their midguts, whereas the DMSO control group did (Figure 2C), most likely because the compound-treated gametocytes did not exflagellate (data not shown).

We further investigated a subset of 18 compounds (Table 2) with reported activity against gametocytes (Bowman et al., 2014; Duffy and Avery, 2013; Ruecker et al., 2014; Sun et al., 2014) and available luciferase-SMFA data using 1,536-well SaLSSA against gametocytes stages I, III, and V. Of this control set, 14 of the 18 were active in at least one stage in SaLSSA with an EC₅₀ of less than 10 μM, and 13 of the 14 were active in SMFAs (Figure S3; Table S5). A possible false-negative compound was MMV665882 (Figure S3G), which showed an incomplete curve in SaLSSA but little activity in the SMFA. This compound showed some activity in viability readouts by others (Duffy and Avery, 2013; Sun et al., 2014). The four potential false

![Figure 2. Screening of the MMV Malaria Box in Comparison to GNF179](image-url)
Table 2. Activity of 18 MMV Control Compounds against Sexual and Asexual Stages

<table>
<thead>
<tr>
<th>Compound</th>
<th>Viability INDEX</th>
<th>EC50 (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stage I</td>
<td>Stage II</td>
</tr>
<tr>
<td>MMV000442</td>
<td>0.120</td>
<td>0.192</td>
</tr>
<tr>
<td>MMV665971</td>
<td>0.056</td>
<td>0.097</td>
</tr>
<tr>
<td>MMV011438</td>
<td>0.005</td>
<td>0.005</td>
</tr>
<tr>
<td>MMV000248</td>
<td>0.006</td>
<td>0.057</td>
</tr>
<tr>
<td>MMV666125</td>
<td>0.006</td>
<td>0.002</td>
</tr>
<tr>
<td>MMV019918</td>
<td>0.017</td>
<td>0.014</td>
</tr>
<tr>
<td>MMV019266</td>
<td>0.028</td>
<td>0.014</td>
</tr>
<tr>
<td>MMV396797</td>
<td>0.034</td>
<td>0.007</td>
</tr>
<tr>
<td>MMV667491</td>
<td>0.037</td>
<td>0.048</td>
</tr>
<tr>
<td>MMV019881</td>
<td>0.063</td>
<td>0.065</td>
</tr>
<tr>
<td>MMV000448</td>
<td>0.066</td>
<td>0.016</td>
</tr>
<tr>
<td>MMV665882</td>
<td>0.116</td>
<td>0.092</td>
</tr>
<tr>
<td>MMV665941</td>
<td>0.157</td>
<td>0.020</td>
</tr>
<tr>
<td>MMV665980</td>
<td>0.240</td>
<td>0.184</td>
</tr>
<tr>
<td>MMV007116</td>
<td>0.377</td>
<td>0.505</td>
</tr>
<tr>
<td>MMV665827</td>
<td>0.592</td>
<td>0.900</td>
</tr>
<tr>
<td>MMV666021</td>
<td>0.610</td>
<td>0.871</td>
</tr>
<tr>
<td>MMV020492</td>
<td>0.768</td>
<td>0.756</td>
</tr>
</tbody>
</table>

The viability index shows the ratio for each gametocyte stage (I–V) compared to DMSO-treated control wells screened at 12.5 µM (384-well TSSA). EC50 values for stage I, III, and V, gametocytes are displayed as mean ± SD (1,536-well SaLSSA, in duplicate). Asexual stage data for 3D7 parasites as provided by MMV and the ChEMBL-NTD repository (https://www.ebi.ac.uk/chemblntd).

*a*72 hr DAPI assay (Duffy and Avery, 2012).

*b*72 hr SYBR green assay (Meister et al., 2011).

Library 2: GNF Malaria Box

To further investigate the rate at which transmission-blocking compounds would be identified in sets of compounds with known blood-stage activity (EC50s of less than 10 µM), we investigated the GNF malaria box (Plouffe et al., 2008). This set of 3,558 compounds was created after screening proliferating asexual parasites at a final compound concentration of 1.25 µM. The set was screened at a single concentration of 1.25 µM against stage V gametocytes with the 384-well SaLSSA. Of these, 145 compounds (4.07%) inhibited stage V gametocytes at greater than 72.3% (Figure S1A). Dose-response analysis showed 108 of the 145 compounds reconfirmed as having activity of less than 1 µM with 22 compounds giving EC50 values below 100 nm against stage V gametocytes. Unlike the clinical antimalarials (Table 1), most of which showed a steep drop-off in activity with mature gametocytes, these scaffolds were almost all equipotent against asexual blood stages and stage V gametocytes. Some of the most active scaffolds (Figure S1B) were carbamazine thioureas (Klayman et al., 1979) as well as napthoquinones, a compound class known to be active against gametocytes (Tanaka et al., 2015). Several of these scaffolds were also active against a P. yoelii hepatocyte development and invasion assay (Meister et al., 2011) that predicts causal prophylactic activity (Figure S1C; Table S3).

Library 3: Broad Diversity-Oriented Synthesis Library

In order to determine the fraction of active compounds that would be found in a larger library that was not preselected for activity against asexual parasites, we tested compounds from the diversity-oriented synthesis (DOS) library (Dandapani and Marcourelle, 2010). This library was designed to populate chemical space broadly with small molecules having both skeletal and stereochemical diversity (Schreiber, 2000).

Two sets of compounds from the DOS library compound collection were screened against stage V using 1,536-well SaLSSA at 2.5 µM in duplicate (Figure S2A). The first was an “informer set,” which includes 9,886 compounds selected to represent a sampling of the structural diversity of all of the DOS scaffolds while also capturing preliminary structure-activity relationships (SARs) and stereochemical structure-activity relationships (SSARs). 25
compounds inhibited stage V gametocytes in both replicates by >30% (Table S4, hit rate 0.25%), and 17 were inconclusive (active in one of two replicates). To reconfirm and investigate the SARs as well as SSARs, 41 compounds were retested in dose-response along with 37 stereoisomers and seven analogs of select compounds. 13 of the hits and one inconclusive exhibited EC₅₀ < 5 μM upon retest, resulting in a retest rate of 23% (or 54% for hits only).

A second compound set included 89 compounds (representing 17 scaffolds) that had previously been shown to have activity in a blood-stage assay against *P. falciparum* Dd2 (EC₅₀ < 2 μM; N.K., unpublished data). These compounds had not been further assessed for mechanism of action or additional stage-specific activity against *Plasmodium* prior to this study. An identical screening pipeline was used for the blood-stage active compounds; in this case, 15 compounds were identified as hits (hit rate 16.9%). These hits and two additional stereoisomers were retested at dose-response, whereupon ten of the compounds exhibited EC₅₀ < 5 μM (retest rate 67%).

Taken together, the 35 hits encompassed 12 different scaffolds, with five singletons and seven scaffolds with two or more representatives. Representatives from six of these scaffolds are shown in Figure S2C; one scaffold was eliminated due to a lack of SSARs and SARs in the hits. While the activity needs to be validated with resynthesized compounds, some of these do show interesting patterns of activity, including one compound with greater activity against gametocytes (BRD0608), four compounds with activity across all three parasite stages, and one compound (BRD1260) with activity against just gametocytes and the asexual blood stages (Figure S2B). Additional studies will be of interest to validate these data and investigate the mechanisms of action of these compounds.

**Cheminformatic Compound Clustering**

To further validate the screens and to identify compounds that can serve as starting points for the development of the transmission-blocking drugs, all compounds that had been screened were hierarchically clustered based on their scaffold similarity. We then identified clusters of structurally related compounds that showed enrichment in the sexual-stage active set at rates higher than expected by chance (Figure 3). For example, a cluster with the highest enrichment score (enrichment log₁₀P = −16.11) consists of 13 compounds related to GNF-PF-3202 and GNF-PF-3600 (dioxanaphthalen-acetamides), with 10 out of 13 compounds being active in the gametocyte assay. Another enriched cluster contains 21 compounds structurally similar to GNF-PF-5511 and GNF-PF-5386 (tetrahydroisoquinolines-4-carboxamides scaffolds that are related to the PfATP4 inhibitor, (±)-dihydroisoquinolones, (+)-SJ733) with seven of the 21 compounds being active (log₁₀P = −7.01). This is not unexpected, given that other PfATP4 inhibitors are active against late-stage gametocytes and (+)-SJ733 potently blocks transmission (Jiménez-Díaz et al., 2014). A final scaffold family that is highly over-represented contains four of the five 2-furancarboxamides (GNF-PF-1329, GNF-PF-3542, GNF-PF-783, GNF-PF-1696, and GNF-PF-2740) in the library (log₁₀P = −7.35), all of which showed moderate activity against stage V gametocytes (0.61 to 0.484 nM) but weaker activity against asexual blood stage parasites (1.72 to > 10 μM). To our knowledge, this compound class has not previously been associated with blocking transmission. These data suggest that screens of very large libraries will likely yield starting points for the discovery of transmission-blocking drugs.

**DISCUSSION**

The present data differ from those that have been reported by a number of other laboratories. Some assays have shown that compounds such as artemether and OZ439 have late-stage gametocytocidal activity of less than 1 μM (Bolscher et al., 2015; Duffy and Avery, 2013). The consensus is that mature gametocytes are resistant to endoperoxides (Delves, 2012; Peatey et al., 2011). Most previous reports combined gametocyte stages for late-stage gametocyte testing (stages III–V or IV–V), which might account for conflicting compound activity (Duffy and Avery, 2013; Lelièvre et al., 2012; Peatey et al., 2011; Sun et al., 2014). Another consideration is that the readout of different gametocytocidal assays might vary with the mode of action of certain drugs, depending on which biological pathway the specific assay is interfering with (Reader et al., 2015).

Overall, our data suggest that low-cost SaLSSA gives few, if any, false positives, compared to available SMFA data. On the other hand, the SaLSSA assay may give a few false-negatives, and will likely miss reversible inhibitors of gamete formation.

In the majority of cases, our data showed that stage V gametocytes had a lower susceptibility to compounds than stage I gametocytes, suggesting decreased metabolic activity during their maturation in preparation for subsequent development in the mosquito midgut. The acquired standard membrane-feeding data, which still represent the gold standard for transmission-blocking activity, suggest that compounds that inhibit stage V gametocytes can block transmission as well. On the other hand, the SMFAs may also find compounds that our cellular assay would miss, including compounds that have a contraceptive effect. Given that fertilization occurs in the mosquito midgut over minutes while late-stage gametocytes can persist in the human body for days, stage V gametocytes are arguably more attractive therapeutic targets.

The data from this study indicate which proteins and pathways might be targeted by transmission-blocking drugs (Figure 4). Compounds that interfere with hemoglobin digestion would be poor candidates for transmission-blocking drugs, although they could yield a reduction in gametocyte numbers as early-stage gametocytes might be killed. In addition, the process of DNA replication should probably not be targeted, nor apicoplast function (azithromycin and doxycycline). Targets for compounds that act against mature gametocytes include proteins that play a role in protein translation (the targets of puromycin, DDD107498, cycloheximide, thiostreptin) and processing, including protein secretion (GNF179), as well as protein degradation (e.g., epoxomycin; Czesny et al., 2009). Interestingly, functional genomic studies had previously shown that gametocytes acquire and store RNA transcripts that rapidly convert to proteins during gamete formation (Mair et al., 2006). Creating a particular vulnerability. Targets involved in maintaining ion homeostasis, such as PfATP4 as well as lipid kinases (e.g., PI4K), are transmission-blocking targets as well as asexual stage targets.
It should be noted that all these targets are also essential for asexual parasites. Targeting exclusively gametocytes could be achieved through inhibiting translational repression, autophagy, sperm function, as well as meiosis. It is expected that compounds inhibiting these processes would be found at lower rates in large libraries, emphasizing the need for ultra-high-throughput...
screens. One example is BRD0608, whose EC50 against asexual blood stages was 15 x higher than against stage V gametocytes and whose selectivity for sexual stages might be improved through medicinal chemistry.

The advantage of compounds like BRD0608 is a reduced potential for emergence of drug resistance. There are billions of asexually replicating parasites in an infected human, each of which has the capacity to develop a drug resistance mutation and pass it on to their progeny. This has been a major reason why malaria control is so difficult.

An open ethical question is whether drugs, which do not relieve malaria symptoms but benefit the community as a whole, should be licensed. Vaccines may be given that provide little relief to an individual—for example, the rubella vaccine in boys, mainly recommended to cohort-protect pregnant women in order to prevent congenital rubella syndrome of newborns. Vaccines are also not without risk, and one could argue that the benefit to humanity that would be achieved with malaria eradication would outweigh the risk.

**EXPERIMENTAL PROCEDURES**

**Gametocyte Culture**

Asexual *P. falciparum* parasites (NF54) were grown at 5% hematocrit in O+ human erythrocytes in serum-containing complete media (RPMI 1640), gentamicin 0.05 mg/ml, hypoxanthine 0.014 mg/ml, HEPES 38.4 mM, sodium bicarbonate 0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 3.4 mM and 0.4% [w/v] 

---

**Compound Assays**

Gametocyte stages I–IV were diluted to 0.50% gametocytemia and 1.25% hematocrit into complete media for the two step protocol (TSSA) or 0.5%–0.75% gametocytemia and 1.25% hematocrit into serum-free SALSSA screening media (RPMI 1640, gentamicin 0.05 mg/ml, hypoxanthine 0.014 mg/ml, HEPES 38.4 mM, sodium bicarbonate 0.2% [w/v], D-glucose 0.2% [w/v], sodium hydroxide 3.4 mM and 0.4% [w/v] AlbuMAX II). Cultures were dispensed (40 μl versus 10 μl) into 384 or 1,536-well plates containing 50 nl or 2.5 nl of compound (final concentration of 1.25 to 12.5 μM) using a MultiFlo dispenser. Plates were incubated at 37°C for 72 hr under low-oxygen conditions. For SALSSA 3 μl (1,536 well) or 10 μl (384 well) of 2.5 μM MitoTracker Red CMXRos and 0.13% saponin solution (w/v) in screening media was added to each well, and plates were incubated for 60–120 min at 37°C. For 384-well TSSA, 5 μl MitoTracker Red CMXRos (5 μM) in screening media was added to each well. After 20 min at 37°C, 5 μl was transferred from the assay plate to a new 384-well imaging plate, that already contained 40 μl MitoTracker Red CMXRos (500nm) in serum-free screening media. For both TSSA and SALSSA, plates were imaged after 30 min incubation.

**High-Content Imaging and Analysis**

Imaging of 384- or 1,536-well plates was performed using a high-content imaging system (Operetta, Perkin Elmer) and Harmony software for image analysis. Viability indices were calculated by dividing the particle count of each compound-treated well by the average particle count of the DMSO wells per plate and range from 0 (active compound) to >1 (inactive). Z values were calculated using DMSO-treated gametocytes as positive and uninfected red blood cells as negative wells.

**SMFA—Traditional**

*P. falciparum* NF54 parasites were grown at 0.5% parasitemia and 5% hematocrit and continuously cultured with daily media changes until they reached stage V [Gregory et al., 2012]. After incubation for 24 hr with compound in DMSO, the SMFA was performed [Gregory et al., 2012]. Briefly, 4- to 6-day-old female *A. stephensi* STE 2 mosquitoes were fed with the treated gametocytes for 15 min using a membrane feeding apparatus. Midguts were dissected after 8 days, and the number of oocysts counted.

**SMFA—Luciferase**

*P. falciparum* NF54-L1 (hsp70-luc reporter) stage V gametocytes were pre-incubated for 24 hr with compound in six dilutions in duplicate. DMSO was
used as negative and DHA as positive control. The compound was washed out, and the gametocytes were fed to Anopheles stephensi mosquitoes. At day 8 post-infection, luminescence signals were determined for 24 individual mosquitoes per cage. EC_{50}s were determined by applying a four parameter logistic regression model. The SMFAs, which were organized by a consortium of laboratories including this one, have been deposited at ChEMBL-NTD (https://www.ebi.ac.uk/chemblntd) and were performed by TropiQ in Nijmegen, The Netherlands.

**P. berghei Liver Stage Invasion Assay**

Liver stage assays were performed as previously described (Baraganà et al., 2015). Briefly, 10^7 P. berghei luciferase-expressing sporozoites (New York University 0.001 strain) were used to infect HepG2-A16-CD81-EGFP cells (pre-treated with compound at 1.25 μM) in a 1,536-well plate. After incubation for 48 hr, 2 μl BrightGlo (Promega) was added, and the EEF growth was quantified by bioluminescence on an Envision Multilabel Reader (PerkinElmer).

**Compound Clustering**

13,844 tested compounds were clustered using the Scaffold Tree algorithm (Schuffenhauer et al., 2007). Each scaffold node was then assigned an enrichment score reflecting the degree of overrepresentation of active compounds (stage V gametocyte inhibitors). We calculated the accumulative hypergeometric p value as probability of observing at least as many hits as we observed within each scaffold. The tree was then pruned, so that only scaffolds with p values < 0.001 were retained. The final resultant tree in Figure 3 was rendered with Cytoscape (version 3.2.0). To focus on those nodes where the scaffold of a node could reasonably resemble the full structures of all associated compound members, the average Tanimoto similarity score between each scaffold node and its associated compounds were calculated based on ChemAxon topological fingerprints (ChemAxon, Kft.), and those tree nodes and leaves with at least 0.85 Tanimoto scores and with at least three hits are highlighted in colors in Figure 3.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes three figures, five tables, and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi.org/10.1016/j.chom.2015.12.001.

**AUTHOR CONTRIBUTIONS**

D.M.P. and M.W. designed experiments, performed screens and dose response assays, analyzed data, and wrote the manuscript; A.Y.D. prepared parasite materials; S.M. performed P. berghei liver stage assay; F.L., K.P., and A.L. performed standard membrane feeding assays; S.L.O. designed experiments; E.L.F. analyzed data; N.K. performed Dd2 blood stage resistance assays, analyzed data, and wrote manuscript. All authors edited the manuscript and contributed to writing.

**ACKNOWLEDGMENTS**

We would like to thank Irwin Sherman and Jeremy Burrows for helpful comments, Omar Vandal for support, Paul Willis for chemical analysis, and TropiQ for the SMFA analysis. This work was supported by the Bill & Melinda Gates Foundation (OPP1040406 to E.A.W. and OPP1032518 to S.L.S.) and the Medicines for Malaria Venture. E.A.W. is supported by grants R01AI103058 and R01AI090141 from NIAID.

Received: September 4, 2015

Revised: November 13, 2015

Accepted: December 11, 2015

Published: December 31, 2015

**REFERENCES**


